Bernardino Rocha, MD
Vascular Surgery · Oklahoma City, OKNPI 1558658815
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $21,860 of the $34,115 with a category attached, or 64.1%. 25 manufacturers reported payments, led by Silk Road Medical, Inc. at 59.8% of the total. Reporting peaked in 2019 at $13,122 and has fallen 97.7% since, to $295 in 2025.
Across 156 payments — averaging $218.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Silk Road Medical, Inc.$20K
- Cardiovascular Systems Inc.$6K
- W. L. Gore & Associates, Inc.$2K
- Endologix LLC$2K
- Asahi Intecc USA, Inc.$1K
- Abbott$662
- plus $3K from 19 others
Across 47 payments — averaging $1896.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$89K
What the payments were for
- Consulting fees$21,86064%
- Travel & lodging$3,95612%
- Food & beverage$8,29924%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Silk Road Medical, Inc. | 36 | $20,405 |
| Cardiovascular Systems Inc. | 17 | $6,034 |
| W. L. Gore & Associates, Inc. | 17 | $1,754 |
| Endologix LLC | 10 | $1,554 |
| Asahi Intecc USA, Inc. | 18 | $1,087 |
| Abbott | 8 | $662 |
| Angiodynamics, Inc. | 5 | $501 |
| Cvrx, Inc. | 3 | $366 |
| Inari Medical, Inc. | 5 | $337 |
| Boston Scientific | 11 | $287 |
| Penumbra, Inc. | 7 | $250 |
| Philips North America LLC | 2 | $225 |
| Cook Medical LLC | 3 | $177 |
| Medtronic | 1 | $123 |
| Balt USA, LLC | 1 | $105 |
| Bard Peripheral Vascular, Inc. | 1 | $53 |
| Stryker | 1 | $51 |
| Surmodics, Inc. | 3 | $31 |
| Nevro Corp. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Lemaitre Vascular, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Terumo Medical Corporation | 1 | $14 |
| Merck | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$20,093
- ENHANCE Transcarotid Peripheral Access Kit$19,801
- ENROUTE Transcarotid Stent System$16,681
- ENROUTE 0.014 Guidewire$16,681
- Diamondback Peripheral$4,919
- ENROUTE Transcarotid Stent$3,413
- ENROUTE .014 Guidewire$3,120
- GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis$1,033
- Diamondback Coronary$775
- AFX$600
- AFX2 Bifurcated Endograft System$517
- Auryon Laser System 100-120 Vac$447
- Barostim Neo System$309
- FLOWTRIEVER CATHETER, S$284
- CT THROMBECTOMY SYSTEM KIT$284
- ASAHI PTCA Guide Wire$244
- JETI$229
- ESPRIT$168
- Asahi Peripheral Vascular Wires$149
- JETi Peripheral Catheter$144
How this compares
$34,115 in reported general payments places this provider in the 80th percentile of 35 vascular surgery providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 49 | $33,396 |
| XareltoRivaroxaban | 24 | $15,426 |
| ClopidogrelClopidogrel Bisulfate | 125 | $1,368 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 196 | $732 |
| Gabapentin | 49 | $657 |
| Doxycycline Hyclate | 25 | $445 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $256 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 47 | $226 |
| Atorvastatin Calcium | 12 | $196 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 14 | $76 |
| Amlodipine Besylate | 17 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $16 | $15,42624 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 35 vascular surgery providers in Oklahoma.
Other vascular surgery in Oklahoma City
- Jim MeltonOklahoma City$131K
- Lenny StubbsOklahoma City$56K
- Ali AminOklahoma City$41K
- Clifford HowellOklahoma City$17K
- Sherisa WarrenOklahoma City$15K
- Jones ThomasOklahoma City$14K
- Trenton KinnearOklahoma City$10K
- Donald SpadoneOklahoma City$9K
- James NeelOklahoma City$7K
- Whitney ThorneOklahoma City$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.